<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997438</url>
  </required_header>
  <id_info>
    <org_study_id>5659</org_study_id>
    <secondary_id>OHSU eIRB#5659</secondary_id>
    <nct_id>NCT00997438</nct_id>
  </id_info>
  <brief_title>Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis</brief_title>
  <official_title>Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portland VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Portland VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about how the antioxidant, lipoic acid, works in the
      body and how it may help in the management of relapsing remitting and secondary progressive
      multiple sclerosis. This study will compare how subject's and healthy volunteers bodies
      absorb and break down the supplement. This information may help in developing new therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects (healthy control, relapsing remitting MS and secondary progressive MS) will be
      recruited through patients of investigators at Portland VA Medical Center (PVAMC), Oregon
      Health &amp; Science University (OHSU), and the community using flyers and word of mouth.

      The following will occur during screening:

        -  Medical History Questionnaire to include questions about drug and alcohol use

        -  Self Administered Expanded Disability Status Scale (EDSS) Questionnaire (MS participants
           only)

        -  Vital Signs (heart rate, respiratory rate, blood pressure) will be measured and recorded

        -  Physical Exam (MS participants only unless necessary, based on the Medical History
           Questionnaire or vital signs, to ensure participant safety)

        -  Neurological Exam (MS participants only unless necessary, based on the Medical History
           Questionnaire or vital signs, to ensure participant safety)

        -  Weight

        -  Urine pregnancy test, if applicable

        -  Anemia testing by finger stick (approximately 1 drop)

      The rest of the study involves

        -  Blood draws before lipoic acid is given, 1 hour, 2 hours, 3 hours, 4 hours, 24 and 48
           hours after LA is given (3 Â½ tablespoons)

        -  Subjects will receive breakfast before they take LA

        -  Subjects will take 4 - 300 mg capsules of lipoic acid (LA) for a total of 1200mg with
           about 1 cup of water

      Blood will be processed to obtain plasma (from which lipoic acid concentrations will be
      measured) and PBMCs (from which cAMP and cytokines/chemokines will be measured).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipoic Acid Levels</measure>
    <time_frame>1 hour</time_frame>
    <description>Plasma concentration of LA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipoic Acid Levels</measure>
    <time_frame>2 hours</time_frame>
    <description>Plasma concentration of LA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipoic Acid Levels</measure>
    <time_frame>3 hours</time_frame>
    <description>Plasma concentration of LA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipoic Acid Levels</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma concentration of LA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipoic Acid Levels</measure>
    <time_frame>24 hour</time_frame>
    <description>Plasma concentration of LA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipoic Acid Levels</measure>
    <time_frame>48 hour</time_frame>
    <description>Plasma concentration of LA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cAMP Levels</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cAMP Levels</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RANTES Levels</measure>
    <time_frame>24 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RANTES Levels</measure>
    <time_frame>48 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MS - Secondary Progressive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg of Lipoic acid supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS - Relapsing Remitting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200mg of Lipoic acid supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg of Lipoic acid supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lipoic Acid</intervention_name>
    <description>300 mg Lipoic acid tablets from Vital Nutrients</description>
    <arm_group_label>MS - Secondary Progressive</arm_group_label>
    <arm_group_label>MS - Relapsing Remitting</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion criteria for MS subjects.

        Inclusion criteria:

          1. Adult at least 18 years of age able to provide informed consent

          2. Currently diagnosed with relapsing remitting or secondary progressive MS

        Exclusion criteria:

          1. Self-reported current substance/alcohol abuse/dependence or sobriety for less than 90
             days

          2. History of traumatic brain injury as defined by a loss of consciousness of greater
             than 30 minutes

          3. History of a medical condition associated with persisting cognitive problems or
             serious central nervous system dysfunction (e.g., brain tumor,dementia)

          4. MS exacerbation within 30 days of study entry

          5. Systemically administered corticosteroids within 30 days of study entry

          6. Pregnant or breast-feeding

          7. Anti-coagulant use such as Heparin, Coumadin, or Aspirin while enrolled in the study

          8. Other significant health problem (e.g. active coronary heart disease, liver disease,
             pulmonary disease, diabetes mellitus) that might increase the risk of subject
             experiencing adverse events

          9. Any condition which would make the subject, in the opinion of the investigator,
             unsuitable for the study

         10. Anemia as indicated by a POC hemoglobin &lt;12

         11. Subjects of child bearing potential or subjects capable of causing pregnancy who are
             sexually active and unwilling to use effective contraceptive methods for the duration
             of the study

        Inclusion/ Exclusion criteria for healthy controls.

        Inclusion criteria:

        1) Adult at least 18 years of age able to provide informed consent

        Exclusion criteria:

          1. Self-reported current substance/alcohol abuse/dependence or sobriety for less than 90
             days

          2. History of traumatic brain injury as defined by a loss of consciousness of greater
             than 30 minutes

          3. History of a medical condition associated with persisting cognitive problems or
             serious central nervous system dysfunction (e.g., brain tumor,dementia)

          4. Pregnant or breast-feeding

          5. Anti-coagulant use such as Heparin, Coumadin, or Aspirin while enrolled in the study

          6. Other significant health problem (e.g. active coronary heart disease, liver disease,
             pulmonary disease, diabetes mellitus) that might increase the risk of subject
             experiencing adverse events

          7. Any condition which would make the subject, in the opinion of the investigator,
             unsuitable for the study

          8. Anemia as indicated by a POC hemoglobin &lt;12

          9. Subjects of child bearing potential or subjects capable of causing pregnancy who are
             sexually active and unwilling to use effective contraceptive methods for the duration
             of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Carr, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Portland VA Medical Center and Oregon Health &amp; Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland VA Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>November 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2017</results_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Portland VA Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Carr</investigator_full_name>
    <investigator_title>Research Career Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited at PVAMC and OHSU January 2012-December 2013 via fliers, word of mouth and MS clinic screening.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MS - Secondary Progressive</title>
          <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
        </group>
        <group group_id="P2">
          <title>MS - Relapsing Remmitting</title>
          <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
        </group>
        <group group_id="P3">
          <title>Healthy Controls</title>
          <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Blood draw difficulty</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusion criteria at visit 1</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MS - Secondary Progressive</title>
          <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
        </group>
        <group group_id="B2">
          <title>MS - Relapsing Remmitting</title>
          <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
        </group>
        <group group_id="B3">
          <title>Healthy Controls</title>
          <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" lower_limit="39" upper_limit="69"/>
                    <measurement group_id="B2" value="51" lower_limit="29" upper_limit="64"/>
                    <measurement group_id="B3" value="49.5" lower_limit="26" upper_limit="65"/>
                    <measurement group_id="B4" value="54" lower_limit="26" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lipoic Acid Levels</title>
        <description>Plasma concentration of LA</description>
        <time_frame>1 hour</time_frame>
        <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remmitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>Lipoic Acid Levels</title>
          <description>Plasma concentration of LA</description>
          <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1376.14" spread="359.41"/>
                    <measurement group_id="O2" value="1609.07" spread="312.47"/>
                    <measurement group_id="O3" value="1428.05" spread="330.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lipoic Acid Levels</title>
        <description>Plasma concentration of LA</description>
        <time_frame>2 hours</time_frame>
        <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remmitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>Lipoic Acid Levels</title>
          <description>Plasma concentration of LA</description>
          <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1125.71" spread="291.40"/>
                    <measurement group_id="O2" value="1167.33" spread="205.02"/>
                    <measurement group_id="O3" value="1348" spread="205.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lipoic Acid Levels</title>
        <description>Plasma concentration of LA</description>
        <time_frame>3 hours</time_frame>
        <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remmitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>Lipoic Acid Levels</title>
          <description>Plasma concentration of LA</description>
          <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667.86" spread="138.24"/>
                    <measurement group_id="O2" value="638.4" spread="114.41"/>
                    <measurement group_id="O3" value="793.89" spread="173.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lipoic Acid Levels</title>
        <description>Plasma concentration of LA</description>
        <time_frame>4 hours</time_frame>
        <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remmitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>Lipoic Acid Levels</title>
          <description>Plasma concentration of LA</description>
          <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.6" spread="73.15"/>
                    <measurement group_id="O2" value="252.75" spread="33.85"/>
                    <measurement group_id="O3" value="394.1" spread="129.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lipoic Acid Levels</title>
        <description>Plasma concentration of LA</description>
        <time_frame>24 hour</time_frame>
        <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remmitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>Lipoic Acid Levels</title>
          <description>Plasma concentration of LA</description>
          <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.13"/>
                    <measurement group_id="O2" value="0.87" spread="0.05"/>
                    <measurement group_id="O3" value="0.78" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lipoic Acid Levels</title>
        <description>Plasma concentration of LA</description>
        <time_frame>48 hour</time_frame>
        <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remmitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>Lipoic Acid Levels</title>
          <description>Plasma concentration of LA</description>
          <population>Plasma samples from one secondary progressive and one healthy control subject did not yield results for unknown reason(s).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.15"/>
                    <measurement group_id="O2" value="0.7" spread="0.05"/>
                    <measurement group_id="O3" value="0.57" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>cAMP Levels</title>
        <time_frame>2 hours</time_frame>
        <population>Useable PBMCs were not obtained from one healthy control and 2 relapsing remitting MS patients</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remmitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>cAMP Levels</title>
          <population>Useable PBMCs were not obtained from one healthy control and 2 relapsing remitting MS patients</population>
          <units>pmol cAMP/mg protein</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" lower_limit="46" upper_limit="101.5"/>
                    <measurement group_id="O2" value="75.8" lower_limit="56.8" upper_limit="113"/>
                    <measurement group_id="O3" value="96.6" lower_limit="75.1" upper_limit="129.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>cAMP Levels</title>
        <time_frame>4 hours</time_frame>
        <population>Useable PBMCs were not obtained from one healthy control and 2 relapsing remitting MS patients</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remmitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>cAMP Levels</title>
          <population>Useable PBMCs were not obtained from one healthy control and 2 relapsing remitting MS patients</population>
          <units>pmol cAMP/mg protein</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" lower_limit="56.8" upper_limit="90.1"/>
                    <measurement group_id="O2" value="79.1" lower_limit="59.9" upper_limit="108.2"/>
                    <measurement group_id="O3" value="103.5" lower_limit="63" upper_limit="149.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RANTES Levels</title>
        <time_frame>24 hour</time_frame>
        <population>Analyses were terminated when it became clear no consistent significant changes in RANTES were taking place.</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>RANTES Levels</title>
          <population>Analyses were terminated when it became clear no consistent significant changes in RANTES were taking place.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47184.9" spread="15986.8"/>
                    <measurement group_id="O2" value="36281.4" spread="13713.1"/>
                    <measurement group_id="O3" value="76751.7" spread="44904.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RANTES Levels</title>
        <time_frame>48 hour</time_frame>
        <population>Analyses were terminated when it became clear no consistent significant changes in RANTES were taking place.</population>
        <group_list>
          <group group_id="O1">
            <title>MS - Secondary Progressive</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O2">
            <title>MS - Relapsing Remmitting</title>
            <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
          </group>
        </group_list>
        <measure>
          <title>RANTES Levels</title>
          <population>Analyses were terminated when it became clear no consistent significant changes in RANTES were taking place.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44905.8" spread="16659.6"/>
                    <measurement group_id="O2" value="42593.8" spread="13848.9"/>
                    <measurement group_id="O3" value="60578.5" spread="21878.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MS - Secondary Progressive</title>
          <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
        </group>
        <group group_id="E2">
          <title>MS - Relapsing Remmitting</title>
          <description>1200mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
        </group>
        <group group_id="E3">
          <title>Healthy Controls</title>
          <description>1200 mg of Lipoic acid supplement
Lipoic Acid: 300 mg Lipoic acid tablets from Vital Nutrients</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Subject fainted and suffered facial abrasions as a result. CT scan and neuro consult determined likely vasovagal reaction causing syncope.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of pre-existing myelopathy</sub_title>
                <description>Subject indicated heat packs used prior to IV made have contributed to exacerbation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sonemany Salinthone</name_or_title>
      <organization>VA Portland Health Care System</organization>
      <phone>5032208262 ext 54394</phone>
      <email>salintho@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

